Patents Examined by Theodore J. Criares
  • Patent number: 6696486
    Abstract: The present invention relates to the use of compounds which act as agonists at atypical beta-adrenoceptors, for the treatment of gastrointestinal disorders, especially peptic ulceration, oesophagitis, gastritis and duodenitis, intestinal ulcerations, including inflammatory bowel disease, and gastrointestinal ulcerations, especially when induced by non-steroidal anti-inflammatory drugs or corticosteroids.
    Type: Grant
    Filed: February 14, 1996
    Date of Patent: February 24, 2004
    Assignee: Glaxo Group Limited
    Inventor: Ashwani Kumar Bahl
  • Patent number: 6696429
    Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4) alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono (C1-C4) alkylamino or a di(C1-C4) alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: February 24, 2004
    Assignee: Ceva Sante Animale
    Inventors: Philippe Du Mesnil, Thierry Bardon, Dominique Thibaud
  • Patent number: 6689816
    Abstract: The present invention describes a novel treatment for neuropsychiatric disorders, including anxiety disorders, mood disorders, psychotic disorders, somatoform disorders, and neuropsychiatric symptoms resulting from movement disorders. The treatment of the present invention utilizes any agent that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate (calcium N-acetylhomotaurinate). Alternatively, separate agents having these activities can be combined as a compound or mixture and thereby administered together. The invention also provides for a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker, that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: February 10, 2004
    Assignee: Synchroneuron
    Inventor: Barry S. Fogel
  • Patent number: 6683108
    Abstract: The present invention makes available methods and reagents for inducing activation of a hedgehog pathway in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as a small molecule, in a sufficient amount to achieve a therapeutic result. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 27, 2004
    Assignee: Curis, Inc.
    Inventors: Anthony David Baxter, Edward Andrew Boyd, Oivin M. Guicherit, Jeffrey Porter, Stephen Price, Lee Rubin
  • Patent number: 6683098
    Abstract: A method of affecting weight loss in humans comprising administering to humans in need thereof with a meal of carbohydrate containing food an amount of miglitol sufficient to lower carbohydrate absorption.
    Type: Grant
    Filed: July 5, 2000
    Date of Patent: January 27, 2004
    Inventor: Harvey Rosner
  • Patent number: 6680310
    Abstract: This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents capable of inhibiting the binding of cortisol to its receptors can be used in methods for preventing antipsychotic-induced weight gain. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The invention also provides a kit for preventing AP-induced weight gain in a human including a glucocorticoid receptor antagonist and instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: January 20, 2004
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Joseph K. Belanoff, Alan F. Schatzberg
  • Patent number: 6677320
    Abstract: The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: January 13, 2004
    Assignee: Hoffmann-La Roches Inc.
    Inventors: Anke Diederich, Pierre Goldbach, Thomas Pfister
  • Patent number: 6673843
    Abstract: Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: January 6, 2004
    Assignee: Emory University
    Inventor: Jack L. Arbiser
  • Patent number: 6673358
    Abstract: Wet wipes impregnated with a solution which includes a mono alkyl phosphate are described. In particular, the solution in the wet wipes includes a phosphate ester surfactant which includes a mono alkyl phosphate having the following structural formula: wherein R represents a saturated or unsaturated hydrocarbon group having an average of from 8 to 22 carbon atoms, x represents a number of 0 to 20, and each of Y and Z represents hydrogen, an alkali metal, ammonium or an alkanol amine. Such wet wipes have improved tactile properties and cleaning efficacy without excessive skin irritation or foaming when compared to conventional wet wipes.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: January 6, 2004
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Douglas Bryan Cole, Katherine Denise Stahl
  • Patent number: 6673831
    Abstract: The instant invention provides methods for preventing or reducing the risk of developing atherosclerosis, as well as for halting or slowing the progression of atherosclerotic disease once it has become clinically evident, comprising the administration of a therapeutically effective amount of an HMG-CoA RI in combination with folic acid or a pharmaceutically acceptable salt or ester thereof to a person who is at risk of developing atherosclerosis or who already has atherosclerotic disease.
    Type: Grant
    Filed: April 27, 1998
    Date of Patent: January 6, 2004
    Assignee: Merck & Co., Inc.
    Inventor: Jonathan A. Tobert
  • Patent number: 6670369
    Abstract: The use of phanquinone for the manufacture of a pharmaceutical composition for the prevention or the treatment of Alzheimer's disease is disclosed. Also methods of treatment or prevention of Alzheimer's disease are disclosed.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: December 30, 2003
    Assignee: P.N. Gerolymatos S.A.
    Inventors: Michel Xilinas, Panayotis Nikolas Gerolymatos
  • Patent number: 6670346
    Abstract: Novel methods for the medical treatment and/or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure: and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3&bgr;,17&bgr;-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and/or sex steroid precursor is disclosed for the medical treatment and/or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: December 30, 2003
    Assignee: Endorecherche, Inc.
    Inventor: Fernand Labrie
  • Patent number: 6664290
    Abstract: This invention relates to a method of limiting postpartum hemorrhage comprising administering orally a single effective dose of misoprostol to a woman during the third stage of labor.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: December 16, 2003
    Assignee: University College London
    Inventor: Hazem El-Rafaey
  • Patent number: 6664246
    Abstract: The present invention is concerned with a pharmaceutical composition suitable for the treatment of cancer and in particular with a pharmaceutical composition containing vitamin D or a precursor, analogue or metabolite thereof and the use of these compositions in the treatment of a tumor in a subject.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: December 16, 2003
    Assignee: MRC Holdings PTY Limited
    Inventor: David Morris
  • Patent number: 6664283
    Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: December 16, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe
  • Patent number: 6660754
    Abstract: This invention is an improved method for reducing or eliminating tobacco usage and the nicotine dependency associated with tobacco usage by gradually decreasing an individual's tobacco consumption over a time period while replacing nicotine from tobacco with an alternative nicotine source.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: December 9, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Theodore K. Kyle, Saul Shiffman
  • Patent number: 6660729
    Abstract: A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compounds.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: December 9, 2003
    Assignee: Cephalon, Inc.
    Inventors: David A. Dickason, Piyush R. Patel, Vincent Corvari, Efraim Shek, Joseph L. Herman, Jeffry M. Skell
  • Patent number: 6656960
    Abstract: A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating the vagus nerve. Disclosed embodiments include positioning one or more electrodes in the esophagus, trachea, or jugular vein, on the neck of the patient, and combinations thereof.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: December 2, 2003
    Assignee: Emory University
    Inventor: John D. Puskas
  • Patent number: RE38386
    Abstract: The instant invention provides a product of manufacture for retarding the biochemical formation of metalloproteinase, including gelatinase, elastase, collaginase, and the like, within the tissues of the body of a patient who has been inflicted with the HIV virus and/or the HIV virus which has advance to the AIDS virus, through the administration of an effective amount of a non-antimicrobial/non-antibiotic/non-antibacterial, chemically modified tetracycline (CMT) analog, its salts, cojugates and/or derivatives, and combinations thereof.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: January 13, 2004
    Inventor: Charles L. Berman
  • Patent number: RE38424
    Abstract: A method of treating a host using taxol comprising administering granulocyte colony-stimulating factor to the host being treated with taxol. The present inventive method allows for increased levels of taxol to be administered to the host in the treatment of various conditions, particularly with respect to ovarian tumors.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: February 10, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Eddie Reed, Elise Kohn, Gisele Sarosy